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COMPARATIVE PREDICTIVE VALUE OF THREE PROGNOSTIC 
MARKERS S-PHASE FRACTION, PCNA AND MITOTIC COUNT ON 
AXILLARY LYMPH NODE METASTASIS IN CARCINOMA BREAST 
Shahid Pervez, Muhammad Nadeem Khan, Muhammad Israr Nasir   
Section of Histopathology, Department of Pathology & Microbiology, The Aga Khan University P.O. Box 3500, Stadium Road Karachi 
Background: Axillary lymph node metastasis is the single most important prognostic factor in 
carcinoma of the breast. Therefore , prognostic markers that may reliably predict probability of 
lymph node (LN) metastases are of great value. This study was conducted to compare the 
predictive value of two novel prognostic / proliferative markers i.e. S-phase fraction (SPF) and 
proliferating cell nuclear antigen (PCNA) in parallel with mitotic index. Methods: Data of 
consecutive cases of infiltrating ductal carcinoma (IDC) breast diagnosed from July 2003 to July 
2004 at the section of the Histopathology, The Aga Khan University Hospital, Karachi, were 
reviewed. A total of 112 cases of infiltrating ductal carcinoma (IDC) of the breast with axillary LN 
sampling were selected. SPF was calculated by flow cytometry while PCNA staining was done by 
immunohistochemistry. Mitotic count was calculated according to modified Bloom and 
Richardson’s grading guidelines. Result: It was observed that the number of axillary LN  
metastases was increased with higher SPF (p value:  0.008). However no significant difference 
was found between the results of various categories of PCNA on axillary LN metastases              
(p value: 0.182) and mitotic count with axillary lymph node metastases (p value: 0.324). 
Conclusion: It was concluded that mitotic count and / PCNA alone cannot be used in predicting 
axillary LN metastases. SPF was found to be a more  reliable marker compared to PCNA reactivity 
and conventional mitotic count in predicting axillary LN metastases.  
Keyword: S-phase fraction, Proliferating cell nuclear antigen, Mitosis, Axillary Lymph node. 
INTRODUCTION 
Breast Cancer is the most common malignancy in 
women in Pakistan. It constitutes approximately 33.4% 
of all cancers in women in Karachi1. There are several 
conventional prognostic markers, which predict the 
overall survival (OS) in breast cancer patients. These 
include tumor size, tumor grade and axillary LN status 
etc. Axillary LN status is considered to be the single 
most important predictor of OS in breast cancer 
patients 2-4. With the passage of time and advancement 
in medical technology a number of novel prognostic 
markers have emerged. These include DNA ploidy5, s-
phase fraction (SPF)5,6, proliferative markers like 
Proliferating Cell Nuclear Antigen (PCNA)7, p-53, C-
Erb-B2/Her2, Cathepsin D, Epidermal Growth Factor 
Receptor (EGFR) etc. According to various studies 
some of these markers are relatively reliable while 
others appear to be of no significance and thus some of 
these markers in different studies contradict each 
other’s results 5,6,8,9 . SPF represents the proportion of 
cells preparing for mitosis by their active replication of 
DNA content in the S-phase of cell cycle8. PCNA 
(Cyclin) is an auxiliary protein of DNA polymerase 
and the level of its synthesis correlates directly with 
rates of cellular proliferation and DNA synthesis. This 
protein is associated with cell cycle & accumulates in 
the nuclei of proliferating cell in the late G1 and S-
phase 10. Mitotic index is defined as the number of 
mitotic figures in any given area of tumor3. In this 
study it was evaluated that among three prognostic 
markers, mitotic count (conventional), PCNA (novel) 
& SPF (novel), we can utilize mitotic count and or 
PCNA alone as an alternate low cost test to predict 
axillary LN metastasis in our breast cancer patients. 
MATERIAL AND METHODS 
The study was conducted in the section of the 
Histopathology at Aga khan university hospital, 
Karachi. Only those cases were included in the study 
in which besides the main tumour, axillary lymph node 
sampling was also done. For mitotic count, modified 
Bloom and Richardson criteria was used. A score of I 
was given to less than 10 mitoses/10hpf, II for 11-19 
mitoses/10 hpf and III for ³ 20 mitoses/10hpf.  
 For PCNA estimation immunohistochemistry 
was employed using PAP method. Anti mouse PCNA 
monoclonal antibody (Clone PC 10), a mouse IgG 
antibody (Dako) was used at a dilution of 1/25. 
Immunostaining was performed on 4mm thick section 
on Poly-L-Lysine coated slides. Diamino-benzidine 
(DAB) was employed as a chromogen. Positive 
staining for PCNA was seen in the nuclei. PCNA 
positivity was divided into two categories.  Positivity 
of 25% nuclei or less was considered as low while 
greater than 25% was regarded as high. 
For estimation of SPF, flow cytometric 
technique was employed using 25 mm thick formalin 
fixed paraffin embedded tissue sections. Sections were 
dewaxed in two changes (2 X 10 minutes) of xylene 
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and rehydrated in 100%, 90%, 70% & 50% of alcohol 
for 10 minutes each. The sections were then rinsed in 
PBS X 10 minutes and incubated in 0.5% Pepsin 
solution at pH 1.5 at 37°C for 30 minutes. Hypodermic 
needles of 40 & 25 bore were then used to break up the 
tissue. Released nuclei were then spun, washed and 
cytopreps made to check their condition. These were 
then stained with Propidium Iodide in isoton 
(250mg/ml) containing 1mg/ml RNAase for 30 minutes 
at 4°C before analysis on FAC Scan (B&D) flow 
cytometer using the software MODFIT version 1.01 
for data acquisition and analysis. Flow cytometric data 
was acquired and displayed in two standard parameter 
dot plots using FL2 width and FL2 areas as the axis. 
This allowed us to draw gates in which debris below 
the first G0/G1 distribution and particles with extended 
time in flight (presumed dublets) were excluded from 
analysis using carefully defined and standardized 
gating criteria. FL2 area signals were then used to 
generate single parameter DNA histograms. A total of 
10,000 nuclei were counted in each case. Specimens 
were rejected if the median half peak coefficient of 
variation (CV) of the diploid peak was more than 5. 
Peak channels of diploid, aneuploid and G2M were 
estimated along with fitting a rectangle between two 
peaks to calculate SPF by MODFIT model. SPF values 
were divided into two categories i.e. equal to or less 
than 10 % was considered as low and greater than 10% 
as high. Axillary LN status was divided into three 
categories i.e. Negative lymph nodes (I), one to three 
lymph nodes positive (II), and four or more lymph 
nodes positive (III).  
 The statistical analysis of the data was 
performed using SPSS 13 software. Students‘t’ test 
and chi square test were employed.  
RESULTS 
A total of 112 cases of IDC of breast were included in 
the study. 24 cases had mitotic score I (less than 10 
mitoses/10hpf), 63 cases had mitotic score II (10-19 
mitoses/10hpf) and 25 cases had mitotic score III 
(³20mitoses/10hpf). It was found that relationship 
between mitotic count and axillary LN metastasis was 
not significant (p value: 0.324). PCNA positivity was 
seen in every case (Fig 1), ranging from 5% to 60%  
(mean 28.25%). In  49 cases , PCNA value was found to 
be equal to or less than 25%, while in the remaining 63 
cases it was greater than 25%. No significant 
correlation was observed between PCNA and axillary 
LN metastasis  (p value: 0.182). S-phase fraction 
ranged from 3.26% to 54.3% (mean 22.83%). As for as 
axillary LN status is concerned, 43 cases had no lymph 
nodes (I), 30 cases had one to three lymph nodes 
positivity  (II), whereas 39 cases  had  four or more 
lymph nodes positivity (III). It was observed that the 
number of axillary LN metastases was higher with 
higher SPF (p value=0.008). 
Table 1- Relationship of mitosis versus axillary lymph 
node metastasis 
 Metastatic LN  (Number) 
Mitosis 0 (1-3) (4 and above) 
Total 
I 8 8 8 24 
II 27 12 24 63 
III 8 10 7 25 
Total 43 30 39 112 
p value = 0.324  
Table 2 - Relationship of PCNA versus axillary lymph 
node metastasis 
 Metastatic LN (Number) 
 PCNA 0 (1-3) (4 or more) 
Total 
£ 25 23 13 13 49 
> 25 20 17 26 63 
Total 43 30 39 112 
p value = 0.182 
Table 3 - Relationship of SPF versus axillary lymph node 
metastasis 
 Metastatic LN  (Number)  
SPF (1-3) (4 or more) Total 
£10 2 1 13 
>10 28 38 99 
Total 30 39 112 
p value = 0.008 
Figure 1 - Photomicrograph of infiltrating ductal 
carcinoma of breast stained with a monoclonal antibody 
against PCNA (PC10). Note brown nuclear staining in a 
large number of tumour cells (Arrow) 
DISCUSSION 
This study did not reveal any significant correlation 
between axillary LN metastases and mitotic count, 
whereas in contrast many other studies did notice 
significant correlation.4,5,11 It may be due to a number 
of factors like variation in selection of the mitotically 
active areas, personal bias on accepting a mitotic 
figure, lack of standardization of the size of hpf etc. 
The authorities recommend that mitotic counts should 
be calculated at ten consecutive most mitotically active 
hpf of the tumour. Secondly to avoid personal bias, 
only clearly identifiable mitotic figures should be 
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counted (like cells in prophase, metaphase and 
anaphase). Similarly size of the hpf should be 
standardized according to modified Bloom and 
Richardson grading criteria3.  
 PCNA is done by a simple 
immunohistochemical technique. In this study 1000 
cell nuclei were counted and then percentage of 
positively stained nuclei was calculated. It is a simple, 
cost effective and non-radioactive technique. However, 
uptill now role of PCNA as a reliable prognostic 
marker is not well established. Lack of association 
between PCNA and axillary lymph node status in our 
study is in agreement with most previous studies7,12,13. 
In studying PCNA mostly PC 10 antibodies were used 
which is substantially affected by fixation. Recently a 
new antibody (19a2) has emerged which is not 
affected much by the duration of fixation. Furthermore 
PCNA may be expressed in response to injury even in 
non-proliferating cells 14. These factors together with 
the findings of our study suggest that PCNA is not a 
consistently useful marker of proliferation nor is it a 
good predictor of axillary LN metastases in breast 
cancer patients. 
 This study, however, identified a significant 
correlation between SPF and axillary lymph node 
metastases. In our study SPF ranged from 3.26% to 
54.30% with a mean of 22.83%. Our mean value was 
found to be higher than those reported by some other 
studies3,15,16. This difference in SPF could be due to 
variation in the interpretation of DNA histogram and 
differences of methodology of flowcytometric 
techniques, staining and sample preparation in various 
centers17.  It is also suggested that the patients in 
Pakistan have a different and more aggressive disease, 
thus more cells are in the synthetic phase of the cell 
cycle8.  In our patients mean tumor size was 5.04 cm 
with a standerd deviation of ± 3.35. 
CONCLUSION 
It was concluded that mitotic count and PCNA alone 
cannot be used to predict axillary LN metastases in 
breast cancer patients. SPF was found to be more 
reliable marker compared to PCNA reactivity and 
conventional mitotic count in predicting axillary LN 
metastases. This could be due to subjective 
interpretation of the latter two markers compared to 
better standardized SPF estimation. 
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